People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Biotechnology, Pharmaceuticals, Biotech / Pharma, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2014 |
| SutroVax, Inc. | — | Biotechnology | Series D+ | $205.9M | $4.5B | 2017 |
| Mirum Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $138.5M | $347.9M | 2018 |
| Collegium Pharmaceutical, Inc | — | Pharmaceuticals | Series C | $97.5M | $701.8M | 2012 |
| Scout Bio, Inc. | — | Biotech / Pharma | Series B | $34.0M | $104.2M | 2018 |
| Silvergate Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $30.8M | $156.4M | 2011 |
| Tobira Therapeutics, Inc. | — | Biotechnology | Series A | $23.2M | $513.3M | 2010 |
| QUATRX PHARMACEUTICALS Co | — | Pharmaceuticals | Series A | $14.0M | $434.4M | 2009 |
| Trubion Pharmaceuticals, Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
| Recida Therapeutics, Inc. | — | Biotechnology | Series A | $5.7M | $204.9M | 2018 |
| Nexcida Therapeutics, Inc. | — | Other | Seed | $2.8M | $51.1M | 2015 |
Patrick Heron at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Patrick Heron on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick J. Heron | 2 | 7 |
| David Socks | 2 | 3 |
| Yigong Ge | 2 | 2 |
| Steven Gillis | 1 | 23 |
| David Hirsch | 1 | 16 |
| Peter Thompson | 1 | 16 |
| Ed Mathers | 1 | 11 |
| Jonathan Leff | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Michael Grey | 1 | 10 |
| Brian Halak | 1 | 10 |
| Patrick Enright | 1 | 10 |
| SCOTT ROCKLAGE | 1 | 9 |
| Tiba Aynechi | 1 | 9 |
| John Freund | 1 | 7 |
| Chen Yu | 1 | 7 |
| Stephen Hoffman | 1 | 7 |
| James Sapirstein | 1 | 7 |
| David Schnell | 1 | 7 |
| Peter Hirth | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.